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Summary 
LR11 (also called SorLA or SORL1) is a type I membrane protein, which was recently identified 
as a biomarker for atherosclerosis and Alzheimer’s disease. We recently reported that LR11 is 
highly expressed in leukemic blasts and its soluble form (sLR11) is significantly elevated in 
acute leukemia patients. Here, we confirmed LR11 expression in follicular lymphoma (FL) cells 
and retrospectively evaluated the prognostic significance of serum sLR11 levels in FL patients. 
LR11 was detected in FL cells by immunohistological staining and flow cytometry. Serum 
sLR11 levels, associated with tumor burden and bone marrow invasion, were significantly 
elevated in untreated FL patients than in normal controls and reduced to the normal range at 
disease remission. Serum sLR11 level was a strong predictor of relapse or progression, with a 
cut-off level of 16.7 ng/mL (AUC 0.9). The 2-year progression-free survival (PFS) was 
significantly lower in patients with high sLR11 levels (≤16.7 ng/mL vs. >16.7 ng/mL; 100% vs. 
31%). Patients with low serum sLR11 levels showed significantly better PFS, regardless of the 
Follicular Lymphoma International Prognostic Index (FLIPI)-2 score. LR11 is a novel 
lymphoma-derived molecule reflecting the tumor burden and organ invasion and may be a 
promising biomarker for FL.  
 
Key Words: LR11, Follicular lymphoma, biomarker, progression free survival, FLIPI-2 
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Introduction 
 
Follicular lymphoma (FL) constitutes approximately 20% of newly diagnosed lymphoma 
patients, making it the second most frequent subtype of non-Hodgkin’s lymphoma (Morton, et al 
2006). It is characterized by an indolent clinical course, with the presence of a chromosomal 
translocation, t(14;18)(q32;q21), or its variants in 85% patients (Yunis, et al 1982), which results 
in the juxtaposition of the immunoglobulin heavy chain gene (IgH) on chromosome 14 with the 
BCL2 oncogene on chromosome 18, leading to constitutive expression of the BCL2 protein 
(Weiss, et al 1987). 
Although the majority of FL patients are indolent for a long period of time, those with 
advanced-stage FL are still incurable by combination chemotherapies, even with 
rituximab-containing regimen (Salles and Ghesquieres 2012). Moreover, clinical behavior is 
markedly heterogeneous, with some patients undergoing progression or transformation early and 
15% of them dying within 2 years of diagnosis (Al-Tourah, et al 2008, van Oers, et al 2010). 
These variable outcomes in FL patients have prompted us to establish reliable prognostic and 
predictive indicators.  
In 2004, the Follicular Lymphoma International Prognostic Index (FLIPI) was proposed on 
the basis of data from more than 4000 FL patients diagnosed between 1985 and 1992 
(Solal-Celigny, et al 2004). Recently, FLIPI was revised to FLIPI-2 by a recent multicenter 
cohort receiving rituximab-containing regimen, incorporating 5 clinical parameters of 
2-microglobulin, lymph node size over 6 cm, bone marrow involvement, anemia, and age over 
60 years (Federico, et al 2009). Although FLIPI-2 was shown to be predictive in progression-free 
survival (PFS), it still remains a clinical surrogate marker, and the development of prognostic 
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indicators that better reflect the biological characteristics of FL may enable a more accurate 
prediction of disease progression. For this purpose, various genetic markers have been proposed 
by gene expression profiling (Byers, et al 2008, Glas, et al 2007). However, these are only 
detectable in tumor specimens obtained by biopsy, when the disease is evident. A widely adapted 
prognostic biomarker that is directly released from FL tumor cells and can be easily quantified 
repeatedly by a simple method has not been established till date. 
LR11 (also called SorLA or SORL1) is a type I membrane protein, and a large extracellular 
part of it is released from the membrane after shedding. It has been shown that LR11 plays a key 
role in the migration of undifferentiated vascular smooth muscle cells (SMCs) and that the 
circulating soluble form of LR11 (sLR11) is a biomarker for atherosclerosis, coronary stenosis, 
and diabetic retinopathy (Jiang, et al 2008, Ohwaki, et al 2007, Takahashi, et al 2012, Yamazaki, 
et al 1996, Zhu, et al 2004). The potent actions of sLR11 in enhancing the migration of SMCs 
and infiltration of macrophages are mediated by the urokinase-type plasminogen activator 
receptor (uPAR)/integrin-mediated activation of focal adhesion kinase (FAK)/ERK/Rac1 
cascades (Jiang, et al 2008, Ohwaki, et al 2007). Circulating sLR11 levels are directly 
proportional to the fractions of migrating vascular SMCs in atherogenesis or to those elicited by 
vascular damage in humans and mice (Jiang, et al 2008, Matsuo, et al 2009, Takahashi, et al 
2010, Takahashi, et al 2012). Moreover, increased sLR11 levels in the cerebrospinal fluid have 
been suggested to predict neurodegeneration in the brain of Alzheimer’s disease patients (Guo, et 
al 2012, Ikeuchi, et al 2010, Matsuo, et al 2009). Thus, serum sLR11 levels appear to reflect the 
pathological conditions of undifferentiated or degenerated cells in various diseases. Along with 
the fact that circulating sLR11 levels represent the accumulation of vascular immature cells, 
human CD34
+
CD38
−
 immature hematopoietic precursors reportedly express high levels of LR11 
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mRNA (Zhang, et al 2000). However, little is known about the expression and role of LR11 in 
human hematopoietic cells. 
We have recently found that LR11 is highly expressed in leukemic cells and that serum 
sLR11 levels in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) 
patients are significantly increased at diagnosis and decreased to normal levels at remission 
(Sakai, et al 2012). We have also found that sLR11 levels are associated with the proportion of 
peripheral leukemic cells (Sakai, et al 2012). This suggests that circulating sLR11 levels are not 
simply associated with numbers or activities of proliferating cells but rather with pathogenic 
properties of immature cells, including their migration and attachment activities. Recent studies 
on humans and animals have shown that sLR11 is produced by myeloid cells after G-CSF 
treatment and that the released sLR11 induces G-CSF-induced leukocyte mobilization into 
circulation through the activation of cell mobility (Shimizu et al, unpublished data). Because 
approximately 40 % of FL patients show bone marrow invasion, we hypothesized that the release 
of sLR11 may play an important role in the development of FL. Subsequently, we analyzed the 
expression profile of LR11 in FL cells and retrospectively evaluated the clinical importance of 
serum sLR11 levels in FL patients. 
 
Methods 
Patients  
Tumor specimens were collected from 16 patients, and serum samples were collected from 61 
patients with newly diagnosed, untreated FL at Chiba University Hospital and affiliated hospitals 
from 2002 to 2012. All patients gave written informed consent for general human bio-specimen 
protocol in accordance with the Declaration of Helsinki. This study was approved by the Human 
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Investigation Review Committee of the Chiba University Graduate School of Medicine or the 
affiliated hospitals. The clinical data were collected retrospectively. 
Clinical stages of the patients were determined according to the Ann Arbor classification 
(Carbone, et al 1971) by means of a physical examination; systemic computed tomography (CT) 
examination; bone marrow aspiration and biopsy; hemogram and differential cell counts; and 
routine biochemical tests. Fifty-two patients (85.2%) were treated with the R-CHOP regimen 
(rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone), 3 patients (4.9%) 
were treated with irradiation only, and 6 patients (9.8%) were observed without treatment. The 
treatment outcome was evaluated by the revised response International Working Group criteria 
(Cheson, et al 2007). Serum samples of the patients were collected at the time of diagnosis, and 
of those who received R-CHOP therapy, paired serum samples could be obtained at the time of 
complete response in 20 patients. As a normal control group, serum samples were collected from 
75 healthy adult volunteers who had given informed consent. 
 
Immunostaing by anti-LR11 antibody 
Formalin-fixed, paraffin-embedded tumor specimens were immunostained with antibody against 
LR11 (clone, A 2-2-3, 50 ng/mL) (Jiang, et al 2008). The specimens were counterstained with 
hematoxylin. As a positive control, each staining batch included a cell block of the U937 human 
leukemic cell line, which shows strong immunostaining against LR11. Samples for LR11 
expression were stratified into three categories, depending on the intensity of LR11 staining. The 
intensity of immunostaining was scored as follows; “weak”, diffuse cytoplasmic staining 
identified only by magnification greater than ×200; “moderate”, cytoplasmic staining with a 
granular pattern; and “strong”, cytoplasmic staining with a granular pattern and juxtamembrane 
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reinforcement.    
 
Flow cytometry 
Lymph node cells were suspended and stained with the fluorescein isothiocyanate 
(FITC)-conjugated anti-LR11 monoclonal antibody M3 (Matsuo, et al 2009, Sakai, et al 2012). 
To identify lymphoma cells, the cells were also stained with antibodies against CD10, CD19, or 
CD20 (Becton Dickinson, CA, USA). The cells were analyzed on BD FACSCalibur (Becton 
Dickinson).  
 
ELISA 
Serum sLR11 levels were determined by sandwich ELISA method, as reported previously 
(Matsuo, et al 2009, Sakai, et al 2012).  
 
Statistical analysis 
Comparisons of serum sLR11 levels between subgroups were made using the Mann–Whitney U 
test. Serum sLR11 levels at diagnosis and remission were compared using Wilcoxon’s 
signed-rank test. Multivariate analysis for factors associated with serum sLR11 levels was 
conducted using a linear regression model. For variable selection, the stepwise procedure was set 
to a threshold of 0.05 for inclusion or exclusion in the model. Overall survival (OS) was defined 
as the time from diagnosis to death due to any cause. PFS was defined as the time from diagnosis 
to death due to any cause or disease relapse or progression. OS and PFS were analyzed by the 
Kaplan–Meier method and the log-rank test, and hazard ratios were calculated using Cox’s 
proportional hazard model. All comparisons were planned, and the tests were 2-sided. P values 
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<.05 were considered statistically significant. Data were analyzed using JMP (version 7.0.2, SAS 
Institute Inc.) and SAS (version 9.2, SAS Institute Inc.) software programs. 
 
Results 
 
Immunostaing and surface expression of LR11 in FL cells 
We evaluated immunohistological staining of LR11 in lymph nodes obtained from 16 FL patients. 
Surface expression and immunohistological profiles of the patients’ specimens are described in 
Table I. LR11 expression was detected in the nodular structures of FL and in the cytosol of 
CD20-positive tumor cells (Figure 1A-C). LR11 staining was detected in all specimens with 
various immunological intensities. “Weak”, “moderate”, and “strong” staining pattern was 
detected in 6 (37.5%), 8 (50%), and 2 (12.5%) samples, respectively. (Figure 1D-F). The 
intensity of staining did not seem to associate with histological grading (Table I); however we 
could not statistically analyze because of the small sample number. Next, we investigated the 
surface expression of LR11 in lymphoma cells obtained from lymph node specimens of 3 FL 
patients by flowcytometry. LR11 expression was confirmed on the surface of CD19-positive FL 
cells (representative data is shown in Figure 2). Thus, LR11 is shown to be expressed in FL cells 
by immunoanalysis using 2 antibodies react against different epitopes of LR11. 
 
Measurement of serum sLR11 levels in FL patients 
Then, we examined the circulatory sLR11 levels of FL patients. Serum sLR11 levels of FL 
patients at diagnosis were significantly higher than those of normal controls (19.4 ± 17.1 vs. 8.8 
± 1.8 ng/mL, P < 0.0001, Figure 3A).  
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Paired sample analysis of 20 patients revealed that sLR11 levels at diagnosis were 
significantly decreased at the time of complete remission (20.7 ± 22.2 vs. 8.2 ± 3.1 ng/mL, P < 
0.0001, Figure 3B). Furthermore, sLR11 levels at complete remission showed no significant 
differences in normal control samples.  
 
Correlations between serum sLR11 levels and clinical parameters of FL 
Next, we evaluated the correlations between serum sLR11 level and various clinical parameters 
to identify the factors associated to serum sLR11 levels. The characteristics of 61 FL patients and 
their individual serum sLR11 levels are shown in Table II. Serum sLR11 levels were 
significantly higher among patients with advanced Ann Arbor staging (P = 0.001), larger 
numbers of nodal sites (P = 0.001), the presence of bone marrow invasion (P < 0.001), the 
presence of bulky disease (P = 0.035), lower hemoglobin levels (P = 0.018), higher serum LDH 
levels (P < 0.001), and higher 2-microglobulin levels (P < 0.001). No significant relationships 
with sex, age, the presence of B symptoms, performance status, and histological grading were 
observed. For determining factors associated with serum sLR11 levels at diagnosis, all 
significant variables were included in multivariate regression analysis, except for “Ann Arbor 
staging,” which showed a relatively strong correlation with “number of nodal sites” (ρ = 0.75, 
P < 0.001). The multivariate linear regression model showed that the presence of bone marrow 
invasion, lower hemoglobin levels, and higher serum 2-microglobulin levels were associated 
with serum sLR11 levels, independently of other risk factors at diagnosis (R
2
 = 0.48, bone 
marrow invasion: P = 0.033, hemoglobin levels: P < 0.001, serum 2-microglobulin levels: P = 
0.029). When the patients were divided according to FLIPI-2, a previously adopted prognostic 
index, patients with “high” FLIPI-2 scores showed significantly higher sLR11 levels than those 
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with “intermediate” and “low” FLIPI-2 scores (29.2 ± 23.9 vs. 13.8 ± 7.7 ng/mL, P < 0.001, 
Figure 4).  
 
Correlation of sLR11 levels with disease progression 
With a median follow-up period of 20.1 months, 2-year OS and PFS of all patients was 96% 
and 69%, respectively. Considering the results obtained from factors associated with serum 
sLR11 levels, we evaluated whether serum sLR11 could be a powerful predictor of disease 
relapse or progression. Eleven patients with “watch and wait” policy and Histological grade 3b 
were excluded from the analysis, since an event for PFS in the “watch and wait” patients and 
treated patients were not comparable, and grade 3b patients were known to follow different 
clinical courses from other histological grading (Horn, et al 2011). Overall, 50 patients were 
included, with a median follow up period of 19.7 months. Their 2-year OS and PFS was 95% and 
66 %, respectively. Receiver operating characteristic curve (ROC) analysis established 16.7 
ng/mL as the cut-off level for disease relapse or progression, with 76% sensitivity and 100% 
specificity, and the maximum area under the curve was 0.9.  
Subsequently, we analyzed the survival according to 2 subgroups divided by serum sLR11 
levels, with the cut-off level of 16.7 ng/mL defined by ROC analysis. Only 2 patients died during 
the observation; therefore, OS between the 2 sLR11 subgroups were not statistically significant 
(2-year OS: 100% vs. 89%, P = 0.096, Figure 5A). 
  However, patients with sLR11 levels higher than 16.7 ng/mL at diagnosis showed significantly 
inferior PFS than those with sLR11 levels equal to or lower than 16.7 ng/mL (2-year PFS: 100% 
vs. 31%, Hazard ratio: 2.3 × 10
7
, 95% CI: not available, P < 0.001, Figure 5B). Furthermore, 
when the patient data were analyzed separately by “low-intermediate” and “high” FLIPI-2 
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scoring, those with higher serum sLR11 levels showed significantly inferior PFS in both the 
FLIPI-2 categories. The 2-year PFS divided by serum sLR11 levels was 100% vs. 75% among 
the “low-intermediate” scoring group (Hazard ratio: 6.85 × 107, 95% CI: not available, log-rank 
P= 0.046, Figure 6A), and the 2-year PFS divided by serum sLR11 levels was 100% vs. 13% 
among the “high” FLIPI-2 scoring group (Hazard ratio: 9.91 × 106, 95 % CI: not available, 
log-rank P = 0.005, Figure 6B). Notably, patients with low sLR11 at diagnosis showed an 
excellent PFS of 100%, regardless of their FLIPI-2 scoring.  
 
Discussion 
  
In this study, we identified LR11 as a novel biomarker, which is expressed in the cytoplasm and 
on the cell surface of FL cells, and the soluble form of which is released and detectable in the 
patients’ serum. Serum sLR11 levels in FL patients were associated with bone marrow invasion, 
lower hemoglobin levels, and elevated serum 2-microglobulin levels. This finding indicates that 
sLR11 levels are not only associated with tumor burden but also possibly with their migration 
and attachment activities, particularly with the affinity for the bone marrow. 
Various predictive indicators for lymphoma have been proposed (Sehn, et al 2012). 
Histological grading and cytogenetics are suggestive for predicting clinical aggressiveness; 
however, the results have been conflicting because of the recent curative potential of 
anthracycline-based treatment strategies (Ganti, et al 2006, Shustik, et al 2011). Improved 
biological insights into the pathogenesis of FL highlighted that interactions between follicular 
tumor cells and non-malignant cells such as T cells, histiocytes, and macrophages modulate the 
growth and survival of FL cells, which has been suggested by gene expression profiling and 
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immunohistological analysis (Camacho, et al 2011, Farinha, et al 2005, Glas, et al 2007, 
Korenberg, et al 2007). However, these strategies still have limitation of technical complexities 
and the results are also conflicting, subsequently limiting the value of molecular indicators. 
Soluble biomarkers are useful tools for evaluating tumor burden and its character. The most 
distinguishable advantage is that they are easy to measure in the patients’ blood sample and can 
be repeatedly evaluated during the clinical course. Various soluble biomarkers have also been 
suggested as prognostic indicators (Charbonneau, et al 2012, Masuda, et al 2008, Shah, et al 
2012, Yang, et al 2011); however, their clinical potential remains to be established. 
  It has been considered that lymphoma cells metastasized to the bone marrow may not have 
been randomly distributed but rather localized to the niches, similar to normal hematopoietic 
precursor cells. Consequently, these micrometastatic lymphoma cells in the bone marrow are 
shown to achieve chemoresistance through VLA-4/VCAM-1-mediated interaction (Weekes, et al 
2001). 
   LR11 can bind to and form complexes with uPAR (Zhu, et al 2004). uPAR is known to 
stimulate tumor cell migration by interacting with integrin-mediated signal transduction (Yebra, 
et al 1999). It is also found to be expressed in disseminated cancer cells in the bone marrow of 
patients with solid cancers, predicting an early relapse (Heiss, et al 2002), and high soluble 
uPAR levels are reported to be associated with poor prognosis in ovarian cancer patients and 
AML (Graf, et al 2005). 
  sLR11 interacts with the uPAR/integrin complex and enhances the mobility of monocytes by 
activating the FAK/ERK/Rac1 cascade in THP-1 macrophages. In addition, sLR11 has been 
shown to increase the migration and adhesion of THP-1 macrophages in a dose-dependent 
manner (Ohwaki, et al 2007). Furthermore, we have recently found that sLR11 stabilize bone 
T Kawaguchi et al.             LR11 in Follicular Lymphoma 
 
13 
 
marrow niche by regulating hypoxia-induced attachment of hematopoietic stem cells to bone 
marrow stroma cells, via uPAR-mediated pathway (Nishii, et al 2013).  These findings suggest 
that sLR11 may enhance cell adhesion-mediated drug resistance by regulating the 
uPAR/integrin-mediated interaction of lymphoma and bone marrow stromal cells. 
  LR11 was immunohistologically detected in various intensities within tumor cells presenting 
various histological grading. Although the sample number was not enough to evaluate 
statistically, immunohistological intensities of LR11 seemed not to have an association with 
histological grading. Moreover, no significant relationship was shown between serum sLR11 
levels and histological grading. These findings suggest that LR11 reflexes different character of 
FL cell from histological grading. 
Although few patients were able to compare, immunohistological intensity did not showed 
significant association with their serum sLR11 levels. We can consider several reasons for this 
phenomenon. First, LR11 might also be released from non-malignant cells; however, this 
hypothesis can be denied because we could not find any non-malignant cells specifically reacted 
against LR11 antibody in the tumor specimens. Second, the release of serum sLR11 might be 
regulated by not only intracellular LR11 expression, but also cell surface shedding mechanism of 
LR11. We have found in several leukemic cell lines that the shedding of LR11 from cell surface 
is regulated by specific tetraspanin co-expressed with LR11 (Tsukamoto et al, unpublished data). 
Therefore, the same mechanism might be found in FL cells. Third, the sensitivity of 
immunostaining might not be enough to reflect the range of serum sLR11 levels. To answer this 
question, we are now evaluating in larger patient cohort to determine the sensitivity and 
specificity of immunostaining method.  
Elevated serum sLR11 levels were a strong predictor of disease relapse, and patients with 
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high serum sLR11 levels showed significantly inferior PFS. The identification of this novel 
circulating biomarker, which directly reflects the biological character of tumor cells, may enable 
a more accurate prediction of tumor burden and activity by a simple method, and it provides new 
insights into the mechanism of tumor progression in FL. 
   Histological grade 3B is generally considered to be more clinically and biologically separate 
from grade 1 to 3A, and similar to diffuse large B cell lymphoma (DLBCL), and a recent study 
addressed that grade 3B showed a plateau in survival curve (Wahlin, et al 2012). Therefore, we 
excluded grade 3B patients from the survival analysis.  
Variables associated with serum sLR11 levels were included in the 5 variables comprising 
FLIPI-2, a widely adapted prognostic indicator for PFS established by a large patient cohort 
(Federico, et al 2009, Numata, et al 2012, Solal-Celigny, et al 2004). The FLIPI-2 index is a 
combination of variables represented by the patient’s condition (age), tumor burden (longest 
diameter of the tumor, β2-microgloblin, and hemoglobin levels), and the character of lymphoma 
cells (bone marrow invasion). Therefore, we consider that serum sLR11 levels more accurately 
reflect the tumor burden and character of lymphoma cells than FLIPI-2. Notably, all patients with 
low sLR11 levels survived without disease progression, regardless of their FLIPI-2 score, 
whereas those with elevated sLR11 levels showed a significantly higher risk of relapse in all 
FLIPI-2 categories. By combining serum sLR11 levels and previous prognostic indexes, we may 
be able to distinguish populations with a high risk of disease progression who require more 
intensive chemotherapy or aggressive strategy such as allogeneic stem cell transplantation. The 
major limitation of our study is that these findings were based on retrospective analysis with a 
limited number of patients. Therefore, a prospective validation study is now in progress to reveal 
the clinical impact of the novel marker LR11 in combination with the established FLIPI-2 score 
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for the determination of patient prognosis.  
  In conclusion, sLR11 is a potential prognostic factor, particularly for identifying patients with 
higher tumor burden and disease activity. Given the current lack of widely established functional 
circulating biomarkers for FL, the identification of a novel lymphoma-derived biomarker will 
elucidate the mechanism of tumor migration and invasion and will ultimately enable us to 
establish a new therapeutic strategy and a potential molecular target. 
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Table I. Immunohistological profiles of LR11 and other surface markers in 
specimens of FL patients  
 
Pt. 
No. 
Histological 
grading 
Surface expression 
by flow cytometry 
Immunohistochimical profile 
Intensity of LR11 
immunostaining 
sLR11 level 
(ng/ml) 
1 NA NA CD20,CD79a,bcl-2 weak 23 
2 3a NA CD10,CD20,CD79a weak 14 
3 2 CD10,CD19,CD20,κ CD10,CD20,CD79a,bcl-2 moderate 90 
4 1 CD10,CD19,CD20,λ CD20 moderate 14.5 
5 3b CD10,CD19,CD20,CD25 CD10,CD19,CD20,bcl-6 moderate 12.9 
6 2 CD10,CD19,CD20,CD23,κ CD20,CD79a,bcl-2 moderate 10.1 
7 3b NA CD10,CD20,bcl-6 moderate 22.9 
8 1 CD10,CD19,CD20,κ CD10,CD20,CD79a,bcl-2 moderate 8.4 
9 1 CD10,CD19,CD20,λ CD10,CD20,CD79a,bcl-2 strong 13 
10 1 CD10,CD19,CD20,κ CD10,CD20,CD79a,bcl-2 strong 9.6 
11 3a CD10,CD19,CD20,CD23,κ CD10,CD20,CD79a,bcl-2 weak 32.3 
12 2 CD10,CD19,CD20,CD23,κ CD10,CD20,CD79a,bcl-2 weak 15.4 
13 1 CD10,CD19,CD20,λ CD10,CD20,bcl-2 moderate 11.1 
14 1 CD19,CD20,λ CD10,CD20,bcl-2 weak 20.9 
15 1 CD10,CD19,CD20,λ CD10,CD20,bcl-2 weak 13.1 
16 NA NA CD10,CD20,bcl-2 moderate 10.7 
NA; not available 
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Table II. Patient characteristics and serum soluble LR11 levels 
 
Variables No. of patients 
(n = 61) 
sLR11 level (ng/mL) 
(mean ± SD) 
P value 
Age 
  ≤60 
  >60 
 
22 
39 
 
19.8 ± 21.4 
19.1 ± 14.4 
0.356 
ECOG Performance status 
  0, 1 
  2–4 
 
53 
8 
 
19.6 ± 17.6 
17.9 ± 14.3 
0.481 
Ann Arbor stage 
  1, 2 
  3, 4 
 
22 
39 
 
12.2 ± 3.9 
23.4 ± 20.2 
0.001 
B symptoms 
  absent 
  present 
 
50 
11 
 
16.3 ± 8.3 
33.2 ± 34.1 
0.237 
Number of nodal areas 
  0–4 
  >4 
 
28 
33 
 
13.8 ± 8.3 
24.1 ± 21.0 
0.001 
Bone marrow invasion 
  absent 
  present 
 
42 
19 
 
13.5 ± 5.5 
32.4 ± 25.4 
< 0.001 
Bulky disease (> 6cm) 
  absent 
  present 
 
51 
10 
 
18.7 ± 18.0 
22.9 ± 11.5 
0.035 
Hemoglobin level  
  ≥ 120 g/L 
  < 120 g/L 
 
49 
12 
 
15.8 ± 8.2 
34.1 ± 31.7 
0.018 
Histological grading 
  1 
  2 
  3a 
  3b 
 
21 
16 
7 
5 
 
14.9 ± 9.7 
24.6 ± 20.6 
16.3 ± 7.8 
15.7 ± 4.2 
NS 
Serum LDH level (IU/L) 
  ≤ULN 
  >ULN 
 
40 
21 
 
14.2 ± 6.8 
29.2 ± 25.2 
< 0.001 
β2-MG level (mg/dL) 
  ≤ULN 
  >ULN 
 
24 
37 
 
11.5 ± 3.7 
24.5 ± 20.1 
< 0.001 
LLN; lower limit of normal, ULN: upper limit of normal, NS; not significant
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Figure legends 
Figure 1. (A-C) Lymph node biopsy specimens from FL patients (Pt. No. 8, described in Table I, 
FL grade 1). (A) Hematoxylin–eosin staining (magnification ×100), (B) CD20 staining 
(magnification ×400), (C) LR11 staining (magnification ×100). 
 (D-F) Lymph node biopsy specimens showing various intensities of immunostaining 
(magnification ×400). (D) Intensity score “weak” (Pt. No. 12, FL grade 2), (E) “moderate” (Pt. 
No. 13, FL grade 1), and (F) “strong” (Pt. No. 9, FL grade 1). 
 
Figure 2. Flow cytometric analysis of FL cells obtained from  FL patient (Pt. No. 13) The solid 
(black) line represents staining with anti-LR11 antibody, whereas the dotted (gray) line 
represents the negative control. 
 
Figure 3. (A) Serum sLR11 levels of FL patients compared with those of normal control subjects. 
(B) Paired sample analysis of serum sLR11 levels at diagnosis and complete remission (CR). 
 
Figure 4. Serum sLR11 levels according to FLIPI-2 scoring. (“int”: intermediate).  
 
Figure 5. (A) OS and (B) PFS according to serum sLR11 at diagnosis. 
 
Figure 6. PFS according to serum sLR11 at diagnosis in patients defined by (A) 
“low-intermediate” and (B) “high” FLIPI-2 scores. 
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FL grade 1). (A) Hematoxylin–eosin staining (magnification ×100), (B) CD20 staining 
(magnification ×400), (C) LR11 staining (magnification ×100). 
 (D-F) Lymph node biopsy specimens showing various intensities of immunostaining 
(magnification ×400). (D) Intensity score “weak” (Pt. No. 12, FL grade 2), (E) “moderate” (Pt. 
No. 13, FL grade 1), and (F) “strong” (Pt. No. 9, FL grade 1). 
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Figure 2. Flow cytometric analysis of FL cells obtained from  FL patient (Pt. No. 13) The solid 
(black) line represents staining with anti-LR11 antibody, whereas the dotted (gray) line 
represents the negative control. 
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Figure 3. (A) Serum sLR11 levels of FL patients compared with those of normal control subjects. 
(B) Paired sample analysis of serum sLR11 levels at diagnosis and complete remission (CR). 
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Figure 4. Serum sLR11 levels according to FLIPI-2 scoring. (“int”: intermediate).  
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Figure 5. (A) OS and (B) PFS according to serum sLR11 at diagnosis. 
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Figure 6. PFS according to serum sLR11 at diagnosis in patients defined by (A) 
“low-intermediate” and (B) “high” FLIPI-2 scores. 
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